October 2025 in “Electronic Theses and Dissertations Repository (University of Pisa)” Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
September 2024 in “Health Sciences” Androgenic alopecia can be treated with minoxidil, finasteride, and hormonal therapy.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia” 7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
4 citations
,
December 2020 in “Scientific Reports” The plant extract mixture improves skin health by reducing inflammation, boosting collagen, and supporting anti-aging.
November 2023 in “Translational Medicine Communications” Derinat may improve hair growth and quality of life in hair loss patients by reducing oxidative stress.
1 citations
,
November 2025 in “Journal of Dermatological Treatment” This prospective cohort study evaluated the real-world effectiveness and safety of Baricitinib in 48 adults with severe alopecia areata over a 12-month period. The study found that Baricitinib is effective and safe for managing severe AA, with the primary endpoint being a SALT score of less than 20% sustained over two consecutive assessments. Favorable responses were associated with lower baseline SALT scores, shorter disease duration, and higher basal erythrocyte sedimentation rates. No serious adverse events were reported, emphasizing the importance of early intervention and appropriate patient selection for optimal outcomes.
74 citations
,
January 2014 in “Journal of Investigative Dermatology” High kallistatin levels in diabetics worsen wound healing by blocking important cell signals.
February 2025 in “Clinical Cosmetic and Investigational Dermatology” Higher fasting insulin levels increase the risk of androgenetic alopecia.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” SM04554 may increase hair growth as a topical treatment for androgenetic alopecia.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” N-acetyl-GED may help prevent and partially reverse a process that leads to scarring hair loss.
Combining β-sitosterol nanoparticles with laser therapy may effectively stimulate hair growth in androgenetic alopecia.
September 2024 in “Egyptian Journal of Dermatology and Venerology” Combining TRA and latanoprost is most effective for treating localized alopecia areata.
4 citations
,
January 2017 in “Biological & pharmaceutical bulletin” Inhibiting ALOX12 can help hair cuticle maturation by increasing S100A3 citrullination.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
3 citations
,
July 2025 in “International Immunopharmacology” August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
29 citations
,
January 2020 in “BioMed Research International” Sinapic acid may help fight obesity and promote hair growth.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.